Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | DUT | P33316 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30923337 | 0.79 | DUT (0.35) | DUT | |
| SCHEMBL12634902 | 0.79 | TAAR1 (0.41) | DUT | |
| SCHEMBL9566221 | 0.79 | TAAR1 (0.41) | DUT | |
| SCHEMBL15054017 | 0.79 | MPO (0.41) | AKR1B1DUT | |
| SCHEMBL30667522 | 0.79 | TAAR1 (0.41) | DUT | |
| SCHEMBL8536947 | 0.79 | TAAR1 (0.41) | DUT | |
| SCHEMBL8069572 | 0.79 | DUT (0.39) | SIGMAR1CYP1A2CYP2C19CYP2C9DUT | |
| SCHEMBL1244866 | 0.79 | TAAR1 (0.42) | DUT | |
| SCHEMBL31530974 | 0.79 | DUT (0.32) | DUT | |
| SCHEMBL15902673 | 0.78 | SLC6A4 (0.40) | MCL1BCHEDUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271988-A1 | METHOD FOR PRODUCING ORGANOMETALLIC NUCLEOPHILE AND REACTION METHOD USING ORGANOMETALLIC NUCLEOPHILE | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271988-A1 | METHOD FOR PRODUCING ORGANOMETALLIC NUCLEOPHILE AND REACTION METHOD USING ORGANOMETALLIC NUCLEOPHILE | HPD, TALDO1, OGG1 | AKR1B1 1777/4885SIGMAR1 3254/4885NQO2 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.